IntraOp Medical Corporation has made history with the successful launch of the world’s first Phase II Electron FLASH Trial. This trial is a groundbreaking advancement in the treatment of nonmelanoma skin cancer (NMSC), as it is the first time a randomized trial has compared FLASH radiotherapy* to conventional radiotherapy. This is the second clinical human trial to utilize the IntraOp® technology, bringing hope to those suffering from NMSC.
The University Hospital of Lausanne (CHUV) in Switzerland is conducting a study to assess the safety and efficacy of Ultra-High Dose Rate (UHDR) radiotherapy (FLASH therapy) in treating localized cutaneous squamous cell or basal cell carcinomas.
By comparing the toxicity and efficacy of FLASH therapy to the standard of care (SOC) conventional radiotherapy, two different irradiation schemes (22Gy single dose radiotherapy and 5 x 6Gy fractionated dose administered in less than two weeks) are being tested. Patient enrollment for the study is currently underway.
Today marks a major milestone in the exploration of FLASH radiotherapy as a viable alternative to conventional radiotherapy. The results of this trial demonstrate the potential of FLASH to provide effective clinical treatment, furthering its potential to become the standard of care. Professor J Bourhis, head of CHUV Radiation Oncology Department, believes this breakthrough is an important step forward in the field of radiotherapy.
FLASH radiotherapy is transforming the way we think about cancer treatment. Delivering ultra-high doses of radiation in mere microseconds, this pre-clinical modality has been shown to spare healthy tissue while minimizing toxicity.
In addition, traditional radiotherapy’s long treatment times and multiple fractionations are no longer necessary. Best of all, pre-clinical studies are suggesting that FLASH may even offer a protective effect for normal tissue, improving the therapeutic index and providing a powerful new weapon in the fight against cancer.
IntraOp is thrilled to continue playing a key part in the revolutionary FLASH study at CHUV. This ground-breaking study is a milestone in the use of electron radiotherapy to provide patient care and demonstrates the potential of this cutting-edge approach. Sanjay Arora, CEO of IntraOp, commented that they “couldn’t be more excited” to be part of this pioneering initiative.
CHUV is a beacon for innovation, offering clinical trials that bring the latest advancements in medicine to patients. A multidisciplinary team of investigators, led by O. Gaide, R. Kinj, W. Jeanneret, F. Duclos, R. Moeckli, P. Jorge, and J. Bourhis, represents CHUV’s Department of Radiation Oncology, Radiation Oncology Laboratory, Institute of Radiation Physics, and Department of Dermatology within Lausanne University Hospital and University of Lausanne, Switzerland. Together, these talented professionals are dedicated to providing the highest quality of care to patients.
FLASH Radiotherapy is revolutionizing the field of cancer treatment with its ultra-high dose rate (UHDR) functionality, which is currently under investigation and has not yet been cleared for sale by the US FDA. It is an exciting development in the fight against cancer and a great hope for patients everywhere.
About IntraOp Medical Corporation
IntraOp is transforming the fight against cancer with its revolutionary Ultra-High Dose Rate (UHDR) radiotherapy system with electrons. By pioneering new advancements in radiotherapy, IntraOp is leading the way in the future of precision therapy.
Based in Sunnyvale, California, IntraOp is committed to accelerating the cure and making a real difference in the lives of cancer patients. With IntraOp, oncologists are equipped with the tools they need to deliver the most advanced treatments and achieve better outcomes.